(Q40162216)

18 September 2017

1 reference

title

Reappraisal of the use of methotrexate in rheumatic disease (English)

1 reference

18 September 2017

1 reference

R. F. Willkens

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6356904

6 October 2023

language of work or name

English

0 references

publication date

1 October 1983

1 reference

18 September 2017

31 October 1983

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6356904

full work available at URL

6 October 2023

https://api.elsevier.com/content/article/PII:0002934383903248?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

https://api.elsevier.com/content/article/PII:0002934383903248?httpAccept=text/plain

6 October 2023

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

American Journal of Medicine

6 October 2023

published in

1 reference

18 September 2017

volume

75

1 reference

18 September 2017

issue

4B

1 reference

18 September 2017

page(s)

19-25

1 reference

Pharmacokinetics of methotrexate

18 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate: clinical pharmacology, current status and therapeutic guidelines

6 October 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis

6 October 2023

5

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Clinical Pharmacokinetics of Methotrexate1

6 October 2023

6

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

The synergistic effect of salicylates on methotrexate toxicity

6 October 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate guidelines--revised

6 October 2023

8

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate: a perspective of its use in the treatment of rheumatic diseases

6 October 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Renal effects of drugs that inhibit prostaglandin synthesis

6 October 2023

10

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

6 October 2023

Methotrexate

11

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate for psoriasis. A new therapeutic schedule

6 October 2023

12

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours

6 October 2023

14

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Treatment of dermatomyositis with methotrexate

6 October 2023

17

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate therapy in polymyositis

6 October 2023

18

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Treatment of polymyositis with immunosuppressive drugs

6 October 2023

19

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Polymyositis and Dermatomyositis: Combined Methotrexate and Corticosteroid Therapy

6 October 2023

20

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Spontaneous Remission or Response to Methotrexate in Sarcoidosis

6 October 2023

21

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate in Reiter's disease

6 October 2023

23

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

The anti-inflammatory effect of some immunosuppressive agents

6 October 2023

24

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Immunosuppressive Effects of Cytosine Arabinoside and Methotrexate in Man

6 October 2023

25

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Sulphasalazine in rheumatoid arthritis

6 October 2023

26

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Antifolate actions of sulfasalazine on intact lymphocytes

6 October 2023

27

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate in the treatment of rheumatoid arthritis; pilot study

6 October 2023

29

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate and fertility in men

6 October 2023

31

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate-induced pneumonitis

6 October 2023

32

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Hypersensitivity reactions to cancer chemotherapeutic agents

6 October 2023

33

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment

6 October 2023

36

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis.

6 October 2023

38

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90324-8

6 October 2023

Identifiers

1 reference

18 September 2017

1 reference